Placental-derived stem cell therapy - Celgene/Human Longevity

Drug Profile

Placental-derived stem cell therapy - Celgene/Human Longevity

Alternative Names: HPDSC; Human placenta-derived stem cells; PSC-100; UCB + HPDSC; UCB and HPDSC

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator Celgene Corporation; Human Longevity
  • Developer Celgene Corporation; Human Longevity; New York Medical College
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological disorders; Haematological malignancies
  • Research Muscular atrophy

Most Recent Events

  • 07 Apr 2016 Phase-I development for malignant and non-malignant Haematological disorders, and early research for Muscular atrophy are ongoing in USA
  • 11 Aug 2014 Early research in Muscular atrophy in USA (IV)
  • 11 Aug 2014 Celgene Cellular Therapeutics and Human Longevity enter into license agreement to develop and co-commercialise PSC 100
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top